The new at-home electrocardiogram monitors could reduce the need for site visits during clinical trials, according to the Dutch medtech giant. At-home ECG is a hot space: iRhythm Technologies CEO Quentin Blackford recently spoke with Medical Design & Outsourcing about iRhythm’s plans to roll out asymptomatic atrial fibrillation (AFib) screening pilots with payors in 2022.
Get the full story on our sister site Medical Design & Outsourcing.